Regenerative Medicine in Plastic Surgery: The Role of Stem Cells and Bioprinting

Regenesis repair rehabilitation., Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Regeneración Dérmica Acelerada con Hidrogel Biotecnológico basado en Exosomas tras Cirugía Correctiva de Síndrome Tarsal: Presentación de un Caso

Estudios y Perspectivas Revista Científica y Académica, Journal Year: 2025, Volume and Issue: 5(2), P. 674 - 683

Published: May 7, 2025

Introducción: Las heridas postquirúrgicas con cierre por tercera intención representan un desafío, especialmente en pacientes comorbilidades que afectan la cicatrización. El uso de exosomas mesenquimales se ha propuesto como alternativa regenerativa. Método: Paciente femenina 59 años espondilitis anquilosante fue tratada AGF BIOMASK, hidrogel y factores crecimiento. Se aplicaron 2 ml goteo cada 72 horas, oclusión mediante parche hidrogel. Resultados: Al tercer día observó 40% cierre; a los 31 días, total sin complicaciones. Evolución dolor, regeneración adecuada. Conclusión: BIOMASK demostró eficacia clínica aceleración cicatrización, proponiéndose una opción segura efectiva medicina regenerativa aplicada complejas.

---

Application of allogeneic adult mesenchymal stem cells in the treatment of venous ulcers: A phase I/II randomized controlled trial protocol

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0323173 - e0323173

Published: May 15, 2025

Objective To evaluate the feasibility, safety and efficacy of cutaneous application Bioengineered Artificial Mesenchymal Sheet (BAMS) in venous leg ulcers (VLUs) versus conventional treatment. Methods This protocol is based on design a Phase I/II, multicenter, randomized, controlled, open-label clinical trial investigating biological dressing supplemented with mesenchymal stem cells (NCT05962931). The being conducted 2 primary care units within Granada Metropolitan Health District. A total 20 patients VLUs are randomized (1:1) into intervention arms: control group treatment group. consists local 4 doses BAMS, administered once per week, while receives therapy. Feasibility will be assessed ability to complete administration at least 80% Safety evaluated by analyzing incidence adverse effects serious effects. Efficacy terms percentage wound closure (measured area reduction), macroscopic assessment lesion (visual analysis RESVECH 2.0 scale), growth factors inflammatory cytokines (ELISA test), pain levels (VAS scale) quality life (CIVIQ 20). Results If confirmed, BAMS-based therapy may provide an effective for VLUs, potentially reducing time associated complications. could significantly enhance patients’ due regenerative analgesic properties dressing. Discussion Given activity cells, accelerated healing effect expected lead shorter times chronic wounds, resulting significant benefits patients, healthcare professionals, overall costs. Trial registration NCT05962931.

Language: Английский

---

Shikonin protects mitochondria through the NFAT5/AMPK pathway for the treatment of diabetic wounds

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 15(12), P. 2338 - 2352

Published: Nov. 14, 2024

Shikonin is a natural remedy that effective at treating diabetic wounds. NFAT5 potential therapeutic target for diabetes, and mitochondrial function essential wound healing. However, the relationship among Shikonin, NFAT5, has not been thoroughly studied. Here, we offer new perspectives on advantages of shikonin managing diabetes.

Language: Английский

---